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Abstract
It is likely that the Mediterranean diet (MedDiet) may mitigate the adverse effects of obesity on the incidence of type 2 diabetes mellitus
(T2DM). We assessed this hypothesis in a cohort of 18 225 participants initially free of diabetes (mean age: 38 years, 61% women). A validated
semi-quantitative 136-item FFQ was used to assess dietary intake and to build a 0–9 score of adherence to MedDiet. After a median of 9·5-year
follow-up, 136 incident cases of T2DM were conﬁrmed during 173 591 person-years follow-up. When MedDiet adherence was low
(≤4 points), the multivariable-adjusted hazard ratios (HR) were 4·07 (95% CI 1·58, 10·50) for participants with BMI 25–29·99 kg/m2 and 17·70
(95% CI 6·29, 49·78) kg/m2 for participants with BMI≥ 30 kg/m2, (v.<25 kg/m2). In the group with better adherence to the MedDiet
(>4 points), these multivariable-adjusted HR were 3·13 (95% CI 1·63, 6·01) and 10·70 (95% CI 4·98, 22·99) for BMI 25–30 and ≥30 kg/m2,
respectively. The P value for the interaction was statistically signiﬁcant (P= 0·002). When we assessed both variables (BMI and MedDiet) as
continuous, the P value for their interaction product-term was marginally signiﬁcant (P= 0·051) in fully adjusted models. This effect
modiﬁcation was not explained by weight changes during follow-up. Our results suggest that the MedDiet may attenuate the adverse effects of
obesity on the risk of T2DM.
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Type 2 diabetes mellitus (T2DM) is considered one of the major
epidemics of the twenty-ﬁrst century. In 2014, WHO estimated
that, worldwide, 422 million suffer from diabetes, almost
doubling the prevalence in 1980(1). This trend is expected to
continue over the coming years, and the International Diabetes
Federation estimates that in 2040 there will be 642 million
people living with diabetes(2). Moreover, T2DM is a leading
cause of many severe complications such as CVD, blindness,
kidney failure and lower limb amputation(3) with the
consequent costs to the healthcare system(4). Therefore, it is
essential to assess lifestyle interventions effects on risk factors
related to T2DM.
Obesity is a major preventable risk factor for T2DM(1,2).
A new approach in the dietary control of overweight and
obesity for the prevention of T2DM should include well known,
healthy (cardio-protective), high-quality and palatable dietary
patterns. One dietary paradigm that may be beneﬁcial in this
context is a traditional Mediterranean diet (MedDiet), relatively
rich in fat from vegetable sources (extra-virgin olive oil, tree
nuts) and including an abundance of minimally processed
plant-foods (vegetables, fruits, whole grains, legumes), moderate
ﬁsh consumption, low consumption of meat and meat products,
and wine in moderation, usually consumed with meals.
Recent studies support that a better adherence to MedDiet
could mitigate the adverse consequences of obesity on CVD
even in obese persons at high cardiovascular risk(5,6). There is
strong evidence that modiﬁcations in the overall dietary pattern
and the adoption of high-quality diets, such as the traditional
MedDiet, together with an intervention aimed to promote
weight loss may play an important role in decreasing the
incidence of T2DM(7–10). Nevertheless, it is not known whether
any dietary change different from weight loss could attenuate
the acknowledged adverse effects of obesity on the risk
of T2DM.
Abbreviations: HR, hazard ratio; MedDiet, Mediterranean diet; PREDIMED, Prevención con dieta Mediterránea; T2DM, type 2 diabetes mellitus.
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In this study we aimed to assess if only changes in the
composition of the food pattern, without any additional weight
loss, physical activity or energy restriction can reduce the
obesity-associated risk of T2DM. We tested the hypothesis that
a higher adherence to a non-energy-restricted MedDiet may
mitigate the adverse effect of obesity on the incidence of T2DM.
Methods
Study population
The Seguimiento Universidad de Navarra (SUN) Project is a
dynamic multipurpose prospective Spanish cohort of university
graduates. This cohort started in 1999 with biennial collection of
updated information through self-administered questionnaires
and it is permanently open to recruitment of new participants.
The aim of this cohort was to assess associations between diet
or lifestyles and the incidence of several chronic diseases and
mortality. Details of the design, methods and objectives of the
SUN Project have been described previously(11,12).
For the present analyses we assessed 22 476 participants who
had answered the baseline questionnaire before December
2015 (Fig. 1). We excluded 406 participants who had prevalent
diabetes at baseline and also participants who had not
remained in the cohort enough time for being followed-up for
at least 2 years (2376). In addition, 1469 participants were
excluded because they reported a total daily energy intake out
of pre-deﬁned limits (>2092 or <23 012 kJ/d (>500 or
<5500 kcal/d) for female, >3347 or <25 104 kJ/d (>800 or
<6000 kcal/d) for male). After exclusions, the ﬁnal population
sample included a total of 18 225 participants.
Ethical approvals
The study protocol was approved by the Institutional Review
Board of the University of Navarra. Voluntary completion of the
ﬁrst questionnaire was considered to imply informed consent.
All clinical investigation were conducted according to the
guidelines laid down in the Declaration of Helsinki and it was
approved by the Human Research Ethical Committee of the
University of Navarra.
Anthropometric variables
Information about weight was recorded at baseline and at each
follow-up questionnaire. BMI, deﬁned as weight in kilograms
divided by the square of height in metres, was calculated in the
baseline questionnaire. Reliability of self-reported weight and
height to compute BMI was assessed in a subsample of the
cohort(13). A high correlation was found with directly measured
weight (r 0·99; 95% CI 0·99, 0·99) and BMI (r 0·94; 95% CI 0·91,
0·97), with mean relative errors of 1·45 and 2·64%, respectively.
Dietary assessment
A validated semi-quantitative 136-item FFQ(14) was used to
assess dietary intakes over the previous year. The validity(14,15)
and reproducibility(16) of this FFQ have been repeatedly
reported. In order to calculate each nutrient score, nutrient
composition of speciﬁed portion sizes (using data from food
composition tables valid for Spain(17,18)) was multiplied by the
frequency of consumption of each participant. Consumption
frequencies were grouped in nine categories (ranging from
never/almost never, to >6 times/d) for each food item. A nine-
item scale proposed by Trichopoulou et al.(19) was used to
classify participants according to their baseline adherence to the
MedDiet(20). One point was assigned to persons whose con-
sumption was above the sex-speciﬁc median of components
most in line with the traditional MedDiet (vegetables, fruits/
nuts, legumes, ﬁsh/seafood, cereals and MUFA:SFA lipid ratio).
One point was assigned to persons whose consumption was
below the sex-speciﬁc median of components against the
traditional MedDiet (meat/meats products, dairy products). For
ethanol, 1 point was assigned to men consuming 10–50 g/d
and to women consuming 5–25 g/d, otherwise, no point
was assigned.
Outcome assessment
Ascertainment of T2DM in the SUN Project has been reported
before(21). Participants who reported at baseline having been
treated with either oral antidiabetic agents or insulin or reported
a medical diagnosis of T2DM were considered prevalent cases
of diabetes at baseline and were excluded. We considered
probable cases of new-onset diabetes to those participants who
reported a T2DM clinical diagnosis during any follow-up
questionnaire but did not have diabetes at baseline(21).
n 22 476 participants recruited
 before February 2016
n 406 with prevalent type 2
diabetes
n 22 070 participants
n 19 694 participants
n 2376 lost to follow-up
n 1469 with extreme energy
intake (sex specific)
Final sample
n 18 225 participants
136 Incident cases of
type 2 diabetes
Fig. 1. Flow chart of participants in the Seguimiento Universidad de Navarra
Project, 1999–2016.
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These participants were asked to conﬁrm their diagnosis with
additional-speciﬁc conﬁrmation questionnaires where they
speciﬁed further details (i.e. type of diabetes, date of diagnosis,
whether the diagnosis was gestational diabetes, highest fasting
glucose value, eventual oral glucose tolerance testing, glyco-
sylated Hb (HbA1c), current use of oral antidiabetic agents or
insulin and occurrence of complications) and to provide a copy
of their medical reports to ensure a sufﬁciently high speciﬁcity
in the classiﬁcation of incident cases. An endocrinologist, blin-
ded to the dietary variables, revised the information collected
with the diabetes-speciﬁc questionnaires and the medical
records of participants to adjudicate new-onset (incident) cases
of T2DM. The American Diabetes Association’s criteria were
used to classify incident cases of T2DM(22).
Other covariates
At baseline questionnaire, information was gathered about
socio-demographic variables (age, marital status, years of
university education), health-related habits (smoking status,
energy intake, physical activity, sedentary lifestyles, hours
of television watching) and clinical variables (medications,
personal history of hypertension, diabetes, hypercholestero-
laemia, cancer, depression, CVD).
Physical activity was assessed at baseline using a previously
validated questionnaire that contained time spent in seventeen
different activities(23). Physical activity was expressed in metabolic
equivalent tasks-h/week as calculated from the time spent at each
activity in h/week multiplied by its typical energy expenditure(24).
The validity of this questionnaire of physical activity was formally
tested in a speciﬁc study within a subset of this cohort(23).
Statistical analysis
We estimated statistical power assuming an absolute total
cumulative incidence of T2DM= 0·8%, sample sizes of 12 000
and 700 in extreme categories of BMI (<25 and >30 kg/m2,
respectively), with expected relative risks between 6 and 8
(a realistic assumption based on previous literature). Under
these assumptions and with a two-tailed α error of 5%, the
expected statistical power will range between 0·78 and 0·84.
Speciﬁcally for interactions, the proposed minimum sample size
in each group to obtain a sufﬁciently high statistical power for
assessing interactions was 900/group in the article by Demi-
denko(25) and we had a similar sample size in our groups.
We examined baseline characteristics of participants stratiﬁed
by their baseline BMI and according to their baseline adherence
to MedDiet. Adherence to MedDiet was categorised into two
groups (≤4 and >4 points in the Trichopoulou’s score).
We used Cox regression models to assess the hazard ratios
(HR) and their 95% CI for incident T2DM across categories of
BMI (cut off points: 25 and 30 kg/m2). Age was used as the
underlying time variable and we stratiﬁed all Cox models by
broad categories of age (decades). The fully adjusted model
included the following potential confounders: sex, year of
recruitment (four categories), adherence to the MedDiet (con-
tinuous within each strata of poor and good adherence);
smoking status (three categories: former smokers, current
smokers and never smokers), physical activity during leisure
time (continuous), hours of television watching, hypertension
status, hypercholesterolaemia status, depression, cancer, CVD,
years of university education, energy intake, marital status,
following special diets and between-meal snacking.
In subgroup analyses we stratiﬁed the results by baseline
adherence to the MedDiet (categorised into two groups: poor
adherence (≤4 points) and good adherence (>4 points).
The P value for multiplicative interaction was calculated by
comparing a full model including a multiplicative interaction
term to a reduced model without an interaction term, using a
likelihood ratio test. We used both a 2 df product-term
(dichotomous MedDiet and three categories for BMI) and a
1 df product-term (both variables as continuous).
To address the possibility that the beneﬁcial effect of the
MedDiet on T2DM might be explained only by changes in
weight during follow-up we conducted an ancillary analysis
where we assessed whether the inverse association between
better adherence to the MedDiet and T2DM was attenuated
after adjusting for weight changes during follow-up.
To assess non-linear associations we ﬁtted fully adjusted
restricted cubic spline models for the association between BMI
and incident diabetes stratiﬁed by adherence to the MedDiet.
A P value <0·05 was considered statistically signiﬁcant.
Analyses were performed using STATA SE version 12.1
(StataCorp LP).
Results
Baseline characteristics of participants stratiﬁed by their base-
line BMI and according to their baseline adherence to MedDiet
are shown in Table 1. Those participants who reported higher
levels of adherence to MedDiet were on average older, more
likely to be married and more physically active. In the baseline
cross-sectional analyses, they also were more likely to have a
previous diagnosis of hypercholesterolaemia, hypertension,
CVD, cancer or depression, probably because these conditions
may have led them to improving their dietary habits. In addi-
tion, these participants with better adherence to the MedDiet at
baseline were also less likely to be current smokers but more
prone to being former smokers. They were also more likely to
follow special diets and to consume more alcohol, but were
less likely to consume snacks between meals.
After a median of 9·5 years of follow-up we observed 136
incident T2DM cases.
The relationship between categories of BMI and the risk of
T2DM according to their baseline adherence to MedDiet (≤4 and
>4 points in the Trichopoulou’s score) is shown in Table 2. We
observed that the HR increased across categories of BMI in both
groups built according to conformity with the MedDiet. However,
after multivariable adjustment, we observed that in the stratum of
low adherence to MedDiet, the obesity-associated HR for T2DM
were signiﬁcantly higher than in the stratum of high adherence to
MedDiet. The P value for multiplicative interaction between
MedDiet and BMI was statistically signiﬁcant (P= 0·002). In fully
adjusted models, the association between BMI and the risk of
diabetes was stronger when the adherence to the MedDiet was
poorer (HR= 2·50; 95% CI 1·93, 3·24 for each additional standard
1480 S. Eguaras et al.
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deviation in BMI) than when the MedDiet score was higher than
4 points (HR 2·01; 95% CI 1·72, 2·36). The P value for interaction
between MedDiet and BMI (both as continuous variables) was
marginally signiﬁcant (P= 0·051). When the non-conﬁrmed
cases were included (in total 169 cases) the results were similar
(and the Pfor interaction became signiﬁcant, P= 0·025).
We conducted an ancillary analysis after adjusting for weight
changes during follow-up. The average yearly weight changes
during follow-up were –0·467 and +0·225kg/year among parti-
cipants who eventually developed and did not develop T2DM
during follow-up, respectively. Therefore, there was no indication
that weight gain during follow-up may explain the development
of T2DM because weight loss (and not weight gain) during
follow-up occurred more likely in cases than in non-cases. After
additionally adjusting for weight changes, the HR for each
additional standard deviation in BMI were 2·31 (95% CI 1·77,
3·01) kg/m2 when adherence to the MedDiet was poor (0–4
points) and 1·95 (95% CI 1·66, 2·30) when it was good (>4 points),
and the interaction remained statistically signiﬁcant (P =0·025).
We ﬁtted spline models to represent graphically the
relationship between baseline BMI and the risk of developing
T2DM during the follow-up period according to baseline
adherence to the MedDiet (≤4 points and >4 points). We
observed that in the group with poor adherence to MedDiet the
Table 1. Baseline characteristics of participants according to their baseline BMI and their adherence to the Mediterranean diet (MedDiet)
(Mean values and standard deviations; percentages)
Low adherence to MedDiet (≤4/9) High adherence to MedDiet (>4/9)
BMI<25 kg/m2 BMI 25–30 kg/m2 BMI>30 kg/m2 P * BMI< 25 kg/m2 BMI 25–30 kg/m2 BMI> 30 kg/m2 P *
n 7111 2136 401 5921 2265 391
Age (years) <0·001 0·031
Mean 33·4 40·8 42·3 37 45·7 46·0
SD 9·6 11·5 12·3 11·5 12·0 11·9
Women (%) 73·3 30·2 30·4 <0·001 75·2 30·6 30·2 <0·001
Year of recruitment 0·004 0·08
Mean 2003 2003 2003 2004 2004 2004
SD 3 3 3 3 3 3
BMI (kg/m2) <0·001 <0·001
Mean 21·6 26·9 32·4 21·8 26·9 32·7
SD 2·0 1·3 2·3 1·9 1·3 3·1
Energy intake (kJ/d) <0·001 0·001
Mean 10 364 9665 9945 11075 10 770 10 941
SD 3188 3117 3372 3276 3272 3527
Energy intake (kcal/d) <0·001 0·001
Mean 2447 2310 2377 2647 2574 2615
SD 762 745 806 783 782 843
Physical activity (METs) <0·001 <0·001
Mean 20·2 20·3 15·7 25·3 23·4 17·5
SD 21·7 21·9 18·2 25·6 22·8 17·1
Marital status (%)
Single 57·6 35 30·9 49·3 26 27·6
Married 39·4 61·3 63·3 46·5 69·1 66·5
Others 3 3·7 5·7 <0·001 4·2 4·9 5·9 <0·001
Smoking
Current smokers (%) 23·4 21·1 20·0 21·6 19·2 18·4
Former smokers (%) 21·1 32·8 37·9 27·8 41·9 46
Never smokers (%) 55·5 46·1 42·1 <0·001 50·7 38·9 35·6 <0·001
Hypercholesterolaemia (%) 10·7 20·1 30·9 <0·001 14·7 30 35 <0·001
Hypertension (%) 2·5 10·3 21·5 <0·001 3·9 15 27·4 <0·001
CVD (%) 0·4 1·3 1·3 <0·001 0·7 2·4 3·1 <0·001
Cancer (%) 2·4 2·6 4·2 0·069 3·1 3·2 3·3 0·916
Depression (%) 4·8 3·4 2·2 0·002 4·4 3·8 3·6 0·327
Years of university education
(%)
Graduate 23·5 17·6 21·0 26·9 21·2 22·3
Postgraduate 48·8 52·9 50·9 47·0 49·7 49·4
Master degree 8·2 8·1 8·7 7·6 7·6 9·2
Doctoral degree 8·6 12·4 9·5 9·2 13·3 9·5
Other 10·9 9·2 10·0 <0·001 9·4 8·2 9·7 <0·001
Television watching (h/week)
Mean 1·6 1·7 1·8 0·001 1·6 1·7 1·8 <0·001
SD 1·2 1·2 1·2 1·2 1·1 1·2
Number of alcohol intake (g/d)
Mean 3·5 5·53 6·2 <0·001 4·7 7·4 9·4 <0·001
SD 6·3 11·3 12·6 7·2 10·1 14·1
Between-meal snacking (%) 37·3 36 54·9 <0·001 30·4 32·2 43·7 <0·001
Following special diets (%) 4·5 7·9 13·7 <0·001 8·1 11·3 17·9 <0·001
* P values for the comparison of percentages or means across the three BMI categories, separately within each group of adherence to the MedDiet (≤4 or >4).
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BMI-associated relative risk of T2DM was visibly higher than in
the group with better adherence (Fig. 2).
Discussion
In this multipurpose cohort of university graduates we observed
an attenuation in the association between high BMI and the risk
of developing T2DM in participants with better adherence to
MedDiet, after adjusting for other common risk factors in T2DM.
This study supports our hypothesis that a higher adherence to
MedDiet could mitigate the pernicious effect of obesity on the
incidence of T2DM even without inducing loss of weight. In fact,
we found a statistically signiﬁcant interaction (assuming a mul-
tiplicative scale for interaction), and our ﬁnding is consistent
with the inverse association between the MedDiet and the risk
of T2DM observed in this cohort(21) and in other previous
studies such as the observational Nurses’s Health Study(26),
the EPIC Study(27) or the Prevención con dieta Mediterránea
(PREDIMED) randomised trial(8,9). In addition, a recent
meta-analysis(28) reported a strong association between better
adherence to MedDiet and a reduction in the risk of T2DM.
Although at baseline we observed that participants with
better adherence to the MedDiet were more likely to have a
previous diagnosis of hypercholesterolaemia, hypertension,
CVD, cancer or depression, these results could be explained
because those differences were based on simple cross-sectional
analyses where reverse causality could not be excluded.
It is well known that there is a strong relationship between
overweight/obesity and the risk of developing T2DM. In fact, the
main measure proposed to prevent T2DM is a weight reduction
through an intervention with diet and lifestyle(29,30–32). Inter-
ventions addressing lifestyles, including physical activity, weight
reductions and energy-restricted diets, have been successful in
achieving a reduction in the incidence of diabetes mellitus in the
Table 2. Relative risks of type 2 diabetes in the Seguimiento Universidad de Navarra project according to baseline BMI and
adherence to Mediterranean diet (MedDiet)
(Hazard ratios (HR) and 95% confidence intervals)
Low adherence to MedDiet (0–4) High adherence to MedDiet (>4–9)
BMI (kg/m2)… <25 25–30 >30 <25 25–30 >30 Pfor interaction
n 7111 2136 401 5921 2265 391
Median BMI 21·6 26·6 31·7 21·8 26·6 31·6
Events 8 27 23 15 37 26
Person-years 69 817 20 430 3604 55 586 20817 3336
Sex-, age-adjusted 0·562
HR 1 4·77 21·16 1 3·52 14·76
95% CI Ref. 1·89, 12·03 7·82, 57·26 Ref. 1·87, 6·63 7·21, 30·22
Multiple adjusted* 0·002
HR 1 4·07 17·70 1 3·13 10·70
95% CI Ref. 1·58, 10·50 6·29, 49·78 Ref. 1·63, 6·01 4·98, 22·99
For each SD in BMI* 0·051†
HR 2·50 2·01
95% CI 1·93, 3·24 1·72, 2·36
Ref., referent values.
* Adjusted for age, sex, recruitment year, smoking (three categories: former smokers, current smokers and never smokers), adherence to the
Mediterranean diet (continuous), hypercholesterolaemia, hypertension, physical activity, marital status, prevalent CVD, prevalent cancer, prevalent
depression, years of university studies, television watching time, snacks intake and special diets. The multiplicative interaction was assessed with a 2 df
product-term (dichotomous MedDiet and three categories for BMI).
† Both the nine-item Mediterranean score and BMI were introduced as continuous variables in the product-term used to assess effect modification.
1 df product-term was used to test the P value of interaction.
Poor adherence to the MedDiet
(≤4/9)
0.1
0.2
0.5
1.0
2.0
4.0
8.0
16.0
32.0
64.0
100.0
200.0
400.0
Ty
pe
 2
 d
ia
be
te
s 
if 
M
ed
Di
et
≤4
/9
17.5 22.5 25.020.0 27.5 32.5 35.030.0
Baseline BMI (kg/m2)
Good adherence to the MedDiet
(>4/9)
0.1
0.2
0.5
1.0
2.0
4.0
8.0
16.0
32.0
64.0
100.0
200.0
400.0
Ty
pe
 2
 d
ia
be
te
s 
if 
M
ed
Di
et
>
4/
9
17.5 20.0 22.5 25.0 27.5 32.5 35.030.0
Baseline BMI  (kg/m2)
Fig. 2. Dose–response association between baseline BMI and the incidence of type 2 diabetes according to baseline adherence to the Mediterranean diet (MedDiet).
The Seguimiento Universidad de Navarra cohort (1999–2015). Values are hazard ratios and 95% CI.
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long term(32,33). However, the role of the overall nutritional
quality in the prevention of T2DM independent of weight
changes, has not been fully addressed by these trials. The
paradigm used in most of these trials, including a recent trial for
cardiovascular prevention in participants who were already
diabetics at baseline (the Look Action for Health in Diabetes
(Look AHEAD) trial(34)), was a low-energy, low-fat diet. In con-
trast with the low-energy, low-fat diet, the MedDiet represents an
updated paradigm of overall dietary quality, with demonstrated
effectiveness and sustainability and with the potential to be
globally applied(10,35,36).
The novelty of our research is the suggestion of a reduction in
the risk of T2DM by the MedDiet that may attenuate the detri-
mental effects of increased body weight. We did extra analyses
in the multivariable adjustment to take into account the
observed yearly average changes in the weight of our partici-
pants, and we did not observe any substantial attenuation of our
results after adjusting for weight changes during follow-up. This
result points to an inherent beneﬁcial effect of a high-quality
overall dietary pattern on diabetes risk independent of weight
loss. Interestingly, our results are in line with recent studies
that assessed a reduction in major CVD events associated
with closer conformity with the MedDiet in obese patients with
high cardiovascular risk, thereby mitigating the adverse effect
of abdominal adiposity(5,6). In this line, the PREDIMED trial
assessed a signiﬁcant reduction in the risk of T2DM(9,37). Our
results are of particular interest in the context of the current
concerns to assess whether interventions with a rationale
different from the Look AHEAD trial(31,32) can provide a better
answer to the current epidemics of obesity and T2DM. Speci-
ﬁcally, the quality of the diet could be a more important factor
for the prevention of T2DM and its cardiovascular complica-
tions than the weight loss(38). A new large trial focused on
MedDiet, weight loss and physical activity (PREDIMED-PLUS)
is ongoing (http://medpreventiva.es/cD5Mp1). Almost 7000
participants have been already randomised to two equally sized
arms in the new PREDIMED-PLUS trial, these two arms are an
energy-restricted MedDiet plus physical activity and weight loss
in the intensive intervention group, but only MedDiet (without
energy restriction or physical activity) in the control group.
They will be in the trial for the next 5 years. The primary end-
point is a composite of hard cardiovascular events (myocardial
infraction, stroke or CVD death). Results are expected in 2021.
An intervention based in an energy-restricted MedDiet together
with physical activity in order to obtain weight loss could
achieve even greater beneﬁts in obese subjects, than the beneﬁt
assessed by the initial PREDIMED study.
Obesity is a well-known risk factor for CVD independent of
BMI(31,39) and the MedDiet could play an important role by
reducing the inﬂammatory mediators involved in the adverse
consequences of abdominal adiposity(7,21,40,41). It is known that
all food intake is accompanied by a mild inﬂammatory oxidative
condition that increases plasma levels of inﬂammatory
biomarkers reducing the sensitivity of tissues to insulin that
leads to a state of insulin resistance(42,43). Plant foods typical of
the MedDiet are rich in antioxidants and anti-inﬂammatory
elements. Their joint and synergistic effects are likely to be
important because the effect of the overall dietary pattern
captures interactions between nutrients and results in a stronger
effect(44). The MedDiet pattern may reduce the risk of T2DM by
increasing adiponectin levels(45), reducing oxidative stress(45,46)
as well as reducing low-grade inﬂammation(47,48).
There are several strengths in our research. We used a cohort
with a prospective design, including a large number of
participants and with a high retention rate. Besides, we used
multiple-adjusted models to control for a wide array of potential
confounders. Our study shows a strong internal validity due
to a high retention rate and sufﬁciently reliable self-reported
measures reported by highly educated participants.
On the other hand, some limitations of our study deserve to
be acknowledged. The information on several variables was
assessed through self-reporting. However, parameters such as
self-reported weight and height or usual diet have been
previously validated in sub-samples of this cohort(13,14).
Another possible caveat might be the fact that the cohort is
composed of middle-aged, highly educated persons, with a
high level of physical activity which could limit the gene-
ralisability of our ﬁndings to other populations. We acknowl-
edge that the SUN cohort is a relatively young cohort for
diabetes research. Previous cohorts have usually included older
participants. The advantage of a younger cohort is that it may
offer unique characteristics to ascertain the earliest steps in the
pathophysiological mechanisms relating dietary exposures to
the risk of T2D. Therefore, our ﬁndings provide interesting
clues with relevance for diabetes prevention research. The
disadvantage of assessing these associations in a young cohort
is that absolute risks are low, and the statistical power might be
limited due to the low number of new cases of T2D. Given that
the participants in our study live in a Mediterranean country,
they are relatively young (mean baseline age was 38 years) and
are, in general, health-conscious subjects, their consumption of
products typical of the traditional MedDiet was high, even in
participants with lower scores of conformity to the MedDiet.
Therefore, under the assumption that the MedDiet plays a
protective role against the development of diabetes, in a cohort
with these characteristics it is not surprising to ﬁnd a low inci-
dence of T2DM. However, our ﬁndings need to be conﬁrmed in
future cohort studies and trials, given the low absolute risks of
T2DM in our cohort of young, slim and highly educated adults.
Conclusions
Our prospective study suggests that a high adherence to Med-
Diet could mitigate the adverse effects of obesity on incidence
of T2DM, without speciﬁcally requiring a loss of weight.
However, due to the low incidence of T2DM further research is
needed to conﬁrm our ﬁndings.
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